entertainment -WSS

entertainment

author：knowledge 2025-09-28 18:40:01 - browse：37192

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Senate panel to vote on hospitals, PBMs, prisoner care

focus

WSS

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Argenx drug significantly slows progression of nerve disorder

Eli Lilly to pay $200M for Beam’s stake in gene

Telehealth options flood the market as retailers push virtual care

Care demand spikes challenge UnitedHealth’s provider arm

leisure time

entertainment

explore

Medicare details structure of new drug price negotiation program

Federal judge rules Oregon’s tough new gun law is constitutional

Jerome Adams on the need for new antivirals for Covid

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Virginia high school admissions case could be legal follow

Congress: Eradicate hepatitis C and reduce the deficit

In age of alternative facts, a scholarly course on calling out crap

Senate panel to vote on hospitals, PBMs, prisoner care

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: What happened with Sarepta's Duchenne data

entertainment

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Telehealth options flood the market as retailers push virtual care

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Georgia court denies Trump's request to quash DA's 2020 election probe

Why police arrested suspected Gilgo Beach killer away from his house

CDC recommends rationing of RSV shot due to shortages

focus

focus

focus

entertainment